VHGI names CEO for MOS
MOS is a provider of solutions to medical practices throughout the US. Simmons will take care of the company’s finances, management, business development, operations, customer growth and general
China-based IMPACT Therapeutics and Pharmanovia have entered an exclusive licensing deal worth up to €423.5m ($488.3m), giving Pharmanovia rights to manufacture, develop, and commercialise senaparib in 66 countries.
CanAm Bioresearch is a contract research organization (CRO) engaged in pre-clinical discovery and development, particularly focused on medicinal chemistry. EpiTherapeutics R&D EVP Lars-Ole Gerlach said they are very